Posts Tagged ‘Featured’

Respiratory diseases—which develop particularly in hospitals, such as those resulting from Pa infections—remain a scourge for which there is currently no effective vaccine. Often resistant to antibiotics, Pa infection is a leading cause of hospital-acquired illness and of infections that are sometimes fatal in people with cystic fibrosis. Glycovax Pharma has optimized manufacturing of the…

Glycovax Pharma has been granted a strategic licence by the NRC to develop a semisynthetic vaccine targeting Pseudomonas aeruginosa — a high-priority pathogen according to the WHO, responsible for severe hospital-acquired infections. This vaccine aims to protect vulnerable individuals, especially those living with cystic fibrosis. Continue reading…